Skip to main content

Are you interested in participating in a clinical trial?

View all available UNC research for Kidney, Liver, and Transplant at Research for Me (UNC based website)

    • A Study of Autologous Neo-Kidney Augment™ (NKA) in Type 2 Diabetics With Chronic Kidney Disease (RMCL-002)
      • Purpose: The purpose of the present study is to compare the safety and efficacy of up to 2 injections of NKA given 3 to 6 months apart (maximum) in subjects who are randomized to receive their first treatment as soon as the NKA product is made available versus subjects who are randomized to undergo contemporaneous, standard-of-care treatment for CKD during the first 12 18 months prior to receiving up to 2 injections of NKA.
      • ClinicalTrials.gov ID: NCT02836574
      • Sponsor: inRegen
      • Status: Enrollment closed, ongoing followup
    • A Study of Autologous Neo-Kidney Augment™ (NKA) in Patients With Diabetic Chronic Kidney Disease (REGEN-003)
      • Purpose: Therapeutic intervention with NKA is intended to delay the need for renal replacement therapy (dialysis or transplant) which, based on the current standard of care, is inevitable for patients with end-stage CKD. The purpose of the present study is to assess the safety and efficacy of up to 2 injections of NKA given 3 months (+12 weeks) apart.
      • ClinicalTrials.gov ID: NCT03270956
      • Sponsor: inRegen
      • Status: Enrollment closed, ongoing followup
    • APOL1 Long-term Kidney Transplantation Outcomes Network
      • Purpose: The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.
      • ClinicalTrials.gov ID:  NCT03615235
      • Sponsor: Wake Forest University Health Sciences
      • Status: Recruiting
    • Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors
      • Purpose: This study utilizes a web-based application to help patients on the organ transplant waitlist and their loved ones communicate a patient’s need for a living donor via social media and provide interested potential donors the opportunity to engage in the evaluation process. Select physicians and research staff from about 15 transplant hospitals will be given access to distribute the application to patients who the above people feel could benefit from the application. After obtaining informed consent, an approved member of the study team will enter the participant’s name, contact info, and organ needed into Donor App’s management portal to send an email or text message with a unique and protected invitation link to the participant. Using this link, the participant will be allowed to draft and publish a story on social media, track engagement through story analytics and invite family members to draft their own stories. Patients who used the Donor App in a pilot study were 6.6 times more likely to have a potential donor contact the center of their behalf. The purpose of this study is to determine the feasibility of implementation of the Donor App at various transplant centers and its efficacy in helping transplant patients achieve transplantation.
      • gov ID: NCT03803423
      • Sponsor: Johns Hopkins University
      • Status: Active, recruiting
    • Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients
      • Purpose: This trial studies whether the nonavalent human papillomavirus vaccine given to adults prior to kidney transplantation can help the body build and maintain an effective immune response during the post-transplant period when they receive immunosuppressive drugs to prevent transplant rejection. This study will help inform our scientific understanding about vaccine-induced immune responses among immunosuppressed individuals.
      • ClinicalTrials.gov ID: NCT03036930
      • Sponsor: National Cancer Institute (NCI)
      • Status: Enrollment closed, ongoing followup
    • Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients (TAC3A5)
      • Purpose: Investigate the direct correlation of CYP3A5 genotype with tacrolimus trough levels and clinical outcomes. The primary endpoint of this study is to evaluate the proportion of patients reaching target levels (8-10 ng/mL) on Day 3 and Day 7 after kidney transplantation.
      • ClinicalTrials.gov ID: NCT03020589
      • Sponsor: University of North Carolina at Chapel Hill
      • Status: Recruiting